| Study | Studied vs control treatments | Type | Study endpoint | Relative effect (95%CI) | x1/n1 x0/n0 | Study risk of bias | Indirectness | Remarks | Tags | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 NCT04304053 | hydroxychloroquine vs standard of care | RCT | hospitalization | 0.75 [0.32;1.77] | -/137 -/157 | some concern |
- | published | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| COPE – Coalition V, 2022 NCT04466540 | hydroxychloroquine vs placebo | RCT | hospitalization | 0.77 [0.52;1.12] | -/689 -/683 | some concern |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PATCH Cohort 1 (Amaravadi), 2021 NCT04329923 | hydroxychloroquine vs standard of care | RCT | hospitalization | 1.79 [0.06;57.93] C | 1/15 0/13 | some concern |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Meta-analysis |
0.77 [0.55; 1.10]
I2 = 0 % |
-/841 -/853 | some concern | no overall indirectness | k=3 studies; N=1,694 patients overall | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of event in experimental group (studied treatment); n1: sample size of experimental group;
x0: number of event in control group (control treatment); n0: sample size of control group; Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s); Conclusive (statistically conclusive): statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Mitja et al. Clin Infect Dis; 2: Amaravadi;
Bayesian (posterior) relative TE 95% CI: 0.77 [0.55; 1.10]
posterior probability of favorable treatment effect (PTE): 92.6 %
some concern risk of bias. This probability should be interpreted according to the risk of bias.
Funnel plot not drawn. Less than 3 points!
Asymetry test p-value = NaN (by Egger's regression)
Funnel plot not drawn. Less than 3 points.
treatments: 657, outcome: 448, pathologies: 97, subgroup: 0, T0: 649,650,589,651